RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
JERSEY, Channel Islands, Sept. 13, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cantor Fitzgerald 2017 Global Healthcare Conference on Wednesday, September 27, 2017 at 8:00 a.m. Eastern Time at the InterContinental New York Barclay Hotel. The Company's Chief Financial Officer, Chris Lindop, will also be participating in the conference.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
